Document Detail

Pathological Complete Response After Neoadjuvant Therapy for Rectal Cancer and the Role of Adjuvant Therapy.
MedLine Citation:
PMID:  23381584     Owner:  NLM     Status:  Publisher    
Both the addition of neoadjuvant chemoradiation therapy and improvements in surgical techniques have improved local control and overall survival for locally advanced rectal cancer patients over the past few decades. The addition of adjuvant chemotherapy has likely improved outcomes as well, though the contribution has been more difficult to quantify. At present, the majority of resected locally advanced rectal cancer patients receive adjuvant chemotherapy, though there is great variability in this practice based on both patient and institution characteristics. Recently, questions have been raised regarding which sub-groups of patients benefit most from adjuvant chemotherapy. As pathologic complete response (pCR) is increasingly found to be a reasonable surrogate for long-term favorable outcomes, some have questioned the need for adjuvant therapy in this select group of patients. Multiple retrospective analyses have shown minimal to no benefit for adjuvant chemotherapy in this group. Indeed, the patients most consistently shown to benefit from adjuvant therapy both in terms of disease free survival (DFS) and overall survival (OS) are those who achieve an intermediate pathologic response to neoadjuvant treatment. Tumors that have high expression of thymidylate synthetase have also shown to benefit from adjuvant therapy. More study is needed into clinical and molecular features that predict patient benefit from adjuvant therapy.
Valerie M Nelson; Al B Benson
Related Documents :
10690854 - Use of long-term intravenous phosphate infusion in the palliative treatment of tumor-in...
24316884 - Treatment of testicular cancer.
640344 - Oral 25-hydroxyvitain d3 in treatment of osteomalacia associated with ileal resection a...
10589824 - Changes in clinical measures of autonomic nervous system function related to cancer che...
20505894 - Risk stratification of patients with locally aggressive differentiated thyroid cancer. ...
22093944 - Treatment outcome after low intensity chemotherapy [cvp] in children and adolescents wi...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-2-5
Journal Detail:
Title:  Current oncology reports     Volume:  -     ISSN:  1534-6269     ISO Abbreviation:  Curr Oncol Rep     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-2-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100888967     Medline TA:  Curr Oncol Rep     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, 60601, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prognostic Significance of Fbw7 in Human Melanoma and its Role in Cell Migration.
Next Document:  An explant assay for assessing cellular behavior of the cranial mesenchyme.